CITIUS PHARMACEUTICALS INC's ticker is CTXR and the CUSIP is 17322U207.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $61 | -84.4% | 89,270 | -72.6% | 0.00% | -100.0% |
| Q2 2023 | $391 | -16.3% | 326,170 | -18.3% | 0.00% | 0.0% |
| Q1 2023 | $467 | +44.6% | 399,270 | -2.4% | 0.00% | – |
| Q4 2022 | $323 | -99.9% | 409,170 | +4.7% | 0.00% | -100.0% |
| Q3 2022 | $473,000 | +35.1% | 390,770 | +2.7% | 0.00% | – |
| Q2 2022 | $350,000 | +400.0% | 380,470 | +868.1% | 0.00% | – |
| Q1 2022 | $70,000 | -96.1% | 39,300 | -95.6% | 0.00% | -100.0% |
| Q3 2021 | $1,804,000 | -72.7% | 888,501 | -53.2% | 0.00% | -75.0% |
| Q2 2021 | $6,606,000 | +275.1% | 1,898,351 | +91.9% | 0.01% | +300.0% |
| Q1 2021 | $1,761,000 | +7904.5% | 989,096 | +4548.7% | 0.00% | – |
| Q4 2020 | $22,000 | -60.0% | 21,277 | -76.9% | 0.00% | – |
| Q1 2020 | $55,000 | +10.0% | 92,300 | +79.8% | 0.00% | – |
| Q2 2019 | $50,000 | -51.0% | 51,333 | -28.2% | 0.00% | – |
| Q1 2019 | $102,000 | +29.1% | 71,533 | -6.0% | 0.00% | – |
| Q4 2018 | $79,000 | -21.0% | 76,133 | +30.5% | 0.00% | – |
| Q3 2018 | $100,000 | – | 58,333 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 314,000 | $559,000 | 0.11% |
| Inspire Advisors, LLC | 110,787 | $197,000 | 0.07% |
| Horst & Graben Wealth Management LLC | 49,590 | $88,000 | 0.03% |
| Freed Investment Group | 14,600 | $26,000 | 0.02% |
| GSA CAPITAL PARTNERS LLP | 57,465 | $102,000 | 0.02% |
| Miller Investment Management, LP | 50,000 | $89,000 | 0.02% |
| LMR Partners LLP | 63,950 | $114,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 50,356 | $90,000 | 0.00% |
| Renaissance Technologies | 989,096 | $1,761,000 | 0.00% |
| WILBANKS SMITH & THOMAS ASSET MANAGEMENT LLC | 20,000 | $36,000 | 0.00% |